All-trans-retinoic acid plays a central role in mucosal immunity, where it promotes its synthesis by upregulating CD103 expression on dendritic cells, induces gut tropic (a4b7 + and CCR9 + ) T cells, and inhibits Th1/Th17 differentiation. Recently, murine studies have highlighted the proinflammatory role of retinoic acid in maintaining inflammation under a variety of pathologic conditions. However, as a result of limited human data, we investigated the effect of retinoic acid on human dendritic cells and CD4 + T cell responses in the presence of polarizing (Th1/Th9/Th17) and inflammatory (LPSinduced dendritic cells) conditions. We report a novel role of retinoic acid in an inflammatory setup, where retinoic acid-primed dendritic cells (retinoic acidmonocyte-derived dendritic cells) up-regulated CCR9 + T cells, which were observed to express high levels of IFN-g in the presence of Th1/Th17 conditions. Retinoic acid-monocyte-derived dendritic cells, under Th17 conditions, also favored the induction of IL-17 + T cells.
Introduction
VA is a crucial immune modulator, as evident from the fact that its supplementation decreases the mortality and morbidity in malnourished children [1, 2] . Dietary VA in the gut is oxidized by RALDH to form RA, the biologically active form of VA [3] . Gut epithelial cells constitutively secrete RA, which in an autocrine manner, up-regulates RALDH expression on LP DCs to form RA-secreting CD103 + DCs. This explains the relatively higher levels of RA in the intestine compared with the rest of the body. In the mesenteric lymph nodes, RA, secreted by CD103 + DCs, differentiates naïve CD4 + T cells into T effector cells that shape the immune response by maintaining gut homeostasis [4] . RA is also crucial in up-regulating the gut homing receptors a4b7 and CCR9 on stimulated T cells, which helps them to translocate and home in the intestine [5] Excessive Th1 and Th17 polarization mounts a potent immune response by secreting proinflammatory cytokines, such as IFN-g, IL-17A, and IL-23, which lead to tissue destruction and autoimmune diseases, such as IBD [6] [7] [8] [9] [10] . Both mice and human studies, so far, have concentrated on the anti-inflammatory role of RA as it inhibits Th1 [11, 12] and Th17 cells [13] , thereby decreasing the mucosal inflammation in humans and EAE severity. In contrast to its antiinflammatory role in attenuating the disease, recent studies have indicated a proinflammatory aspect of RA in maintaining the disease activity. Experiments with murine models have reported that RA helps to maintain Th1 lineage [14] and is essential for the production of IFN-g and IL-17 from Th1 and Th17 cells, respectively [15] .
Th9 cells are the recently identified Th cell subset, induced in the presence of IL-4, IL-2, and TGF b [16] , producing IL-9. Th9 cells have been shown to be increased in experimental infection [17] , allergic [18] , and ulcerative colitis patients [19] , thus emerging as a proinflammatory effector T cell subset. However, the exact role of Th9 cells in the context of inflammation is poorly understood, as some studies also point toward its anti-inflammatory nature [20] [21] [22] .
Moreover, the effect of RA on Th9 differentiation has not been investigated.
Although the proinflammatory role of RA has been studied primarily in murine models, there are very few reports on how RA regulates T cells during inflammation in humans. Therefore, the goal of our study was to investigate how RA, under inflammatory conditions, plays a critical role in immune regulation in different polarizing conditions. Here, we report that in a human setting, RA exerted a contrary role, by priming the CD103 + DCs, which differentiated CCR9 + and a4b7 + T cells and induced IFN-g, irrespective of the specific polarizing conditions, and IL-17 under Th17 condition. Collectively, these data suggest a plausible role of RA in sustaining and aggravating the inflammation.
MATERIALS AND METHODS

T cell isolation and stimulation
Peripheral venous blood was obtained from healthy volunteers after written, informed consent. The study was approved by the Institutional Ethics Committee. PBMCs were separated by Ficoll-Paque Plus (GE Healthcare, Piscataway, NJ, USA) gradient centrifugation. The PBMCs were stained with CD4-PE, CD25-PE-Cy7, and CD45 RA-APC (BioLegend, San Diego, CA, USA). Naive T cells (CD4 + CD25 2 CD45RA + ) were sorted by high-speed flow cytometry with FACSAria III (BD Biosciences, San Jose, CA, USA) to .95% purity after postsort analysis. Cells (10 5 )/well were cultured for 6 d in a 96-well U-bottom plate in serum-free X-VIVO medium (Lonza, Walkersville, MD, USA) and stimulated with plate-bound anti-CD3 (UCHT1; 5 mg/ml) and soluble anti-CD28 (28.2;1 mg/ml). Wherever indicated, TGF-b1 (5 ng/ml); IL-1b (12.5 ng/ml); IL-6, IL-21, and IL-23 (all at 25 ng/ml) for Th17, TGF-b1 (5 ng/ml) and IL-4 (10 ng/ml) for Th9, and IL-12 (10 ng/ml) for Th1 were added at the start of the culture.
In vitro generation of MoDCs
Monocytes were purified from PBMCs by a negative-selection process using CD14 MicroBeads (Miltenyi Biotec, Auburn, CA, USA). The monocytes were cultured at 37°C in 5% CO 2 for 6 d in RPMI-1640 medium (Thermo Fisher Scientific Life Sciences, Waltham, MA, USA) containing 10% FBS (Thermo Fisher Scientific Life Sciences) in the presence of 100 ng/ml GM-CSF (PeproTech, Rocky Hill, NJ, USA) and 50 ng/ml IL-4 (PeproTech). RAMoDCs were generated with addition of 500 nM RA (Sigma-Aldrich, St. Louis, MO, USA) to the same culture conditions as Mo-DCs. For differentiation into mature DCs, the cultures in the presence and absence of RA were stimulated with LPS for 48 h. On d 7, the mature DCs were analyzed for surface molecule expression using the following antibodies: anti CD11c (V450), anti-HLA-DR (PerCP/Cy5.5), anti-CD83 (APC), anti-CD86 (PE/Cy7), anti-CD103 (PE), and anti-PDL-1 (PE; all from BD Biosciences).
DC/T cell coculture assays
Mature MoDCs and RA-MoDCs were cocultured with naïve CD4 + T cells (1:10) in 96-well flat-bottom plates in RPMI-1640 medium containing 10% FBS. When indicated, TGF-b1 (5 ng/ml) and IL-4 (10 ng/ml; Th9 conditions), 
Flow cytometry
For analyzing intracellular cytokine production, cells cultured under specific conditions on d 7 were restimulated with PMA (50 ng/ml; Sigma-Aldrich), ionomycin (500 ng/ml; Sigma-Aldrich), and Golgi stop (BD Biosciences) for 4 h at 37°C. Cells were stained with LIVE-DEAD stain for 5 min at 4°C to gate out dead cells. Afterward, the cells were fixed and made permeable with Perm/Wash Buffer (BD Biosciences) for 15 min on ice, followed by intracellular cytokine staining. For CFSE labeling, naive (at d 0 culture) or activated (at the end of d 6 culture) T cells were washed twice with PBS/0.1% FBS and labeled with the CellTrace CFSE cell proliferation kit (Thermo Fisher Scientific Life Sciences), according to the manufacturer's instructions. Data were acquired on a FACSVerse (BD Biosciences) and analyzed using FlowJo software (Tree Star, Ashland, OR, USA).
Real-time PCR
T Cell and DC mRNA were isolated using the RNeasy Mini kit (Qiagen, Venlo, The Netherlands) and converted to cDNA using the iScript cDNA Synthesis Kit (Bio-Rad Laboratories, Hercules, CA, USA). The probes used were the following: GAPDH: Hs02758991_g1; RORC: Hs01076112_m1; TBX21: Hs00203436; IRF4: Hs01056533_m1; ITGAE: Hs01075372_m1; and ALDH1A2: Hs00180254. The quantification was performed on the QuantStudio 7 Flex PCR system (Thermo Fisher Scientific Life Sciences). The target gene was normalized to GAPDH, and the fold change was calculated as 2 2 ΔΔCT comparative threshold.
Statistical Analysis
Two-tailed Student's t test was performed to analyze the paired observations. Bar graphs represent means 6 SEM. P , 0.05 was considered significant. All statistical calculations were done using GraphPad Prism 5.0 software (La Jolla, CA, USA).
RESULTS
RA inhibits IFN-g, IL-17, and IL-9 production in CD4 + T cells
To investigate the effect of RA on CD4 + T cell differentiation, we first stimulated sorted, naïve CD4 + CD25 2 CD45RA + T cells with plate-bound anti-CD3 and soluble anti-CD28 and skewed to different polarizing conditions (Th1, Th17, and Th9) in the presence or absence of RA (100 nM). Indeed, in Th1 and Th17 Interestingly, RA also inhibited IFN-g expression in a Th17 polarizing condition (Fig. 1B) . The effect of RA was evident on the expression of master transcription factors TBX21, and RORC, which are essential for Th1 and Th17 differentiation, respectively (Fig. 1C) .
It is well known that RA induces FOXP3 + T regs ; therefore, we checked whether RA would affect the FOXP3 expression on Th17 cells (Fig. 1B) . As expected, RA induced FOXP3 expression in a Th17 polarizing condition.
TGF-b plays an important role in FOXP3 + T reg conversion and together with IL-4, in Th9 development [23] . Studies have shown that RA synergizes with TGF-b to induce T regs [13, 24] and reciprocally inhibit development of Th17 cells induced by TGF-b/IL-6/IL-1b/IL-21/IL-23 [25] . However, there are no reports how RA affects Th9 cells. Therefore, we investigated the effect of RA on CD4 + T cells in Th9 polarizing conditions. Interestingly, RA significantly decreased IL-9 expression ( Fig. 2A) while inducing FOXP3 on CD4 + T cells (Fig. 2B) . As RA inhibited IFN-g in both Th1 and Th17 conditions, we further checked whether similar results came in the Th9 condition. Similar to Th1/Th17, IFN-g expression was also inhibited in Th9-polarizing condition ( Fig. 2A) . IRF4 has been shown to play a central role in Th9 differentiation [26] . We observed that IRF4 mRNA expression was also decreased in the presence of RA, indicating that RA inhibits Th9 differentiation (Fig. 2C) .
Inhibition of IFN-g, IL-17, and IL-9, while inducing FOXP3 expression, indicates the anti-inflammatory role of RA in ex vivo expanded CD4 + T cells.
RA up-regulates CD103 expression and gut-homing receptors on MoDCs
After identifying the effect of RA on naïve CD4 + T cells in vitro, we tried to determine the effect of RA on the DC and CD4 + T cell interaction. For this, we generated MoDCs by incubating CD14 + cells from healthy human volunteers with GM-CSF and IL-4 in the presence or absence of RA. It is evident from previous studies that CD103, a molecule that confers the ability on DCs to synthesize RA, is highly up-regulated in the presence of RA (Fig. 3A) . Both RA-MoDCs and MoDCs matured on stimulation with LPS, as assessed by increased expression of the costimulatory molecules CD83, CD86, and HLA-DR (Fig. 3B) . Interestingly, expression of CD83, CD86, and HLA-DR was down-regulated on RA-MoDCs compared with MoDCs (Fig. 3C) . However, both RAMoDCs and MoDCs were CD11c + and did not express CCR6, which is expressed on other DC subsets (data not shown). PDL-1 binds to PD-1 on T cells and initiates inhibitory signals leading to inhibition of T cell differentiation. However, there was no change in PDL-1 expression in RA-MoDCs and MoDCs (Fig. 3C) , indicating that RA priming did not affect the T cell proliferation. This was validated further using CFSE experiments (Supplemental Fig. 1A) . CD103 + DCs synthesize RA as a result of the presence of RA synthesizing enzyme-retinol dehydrogenase and RALDH. Therefore, to evaluate the RA synthesis ability of the RA-MoDCs, we checked the mRNA expression of the ALDH1A2 gene encoding RALDH2, a dominant isoform present in the small intestine. As expected, elevated expression of ALDH1A2 was found in RA-MoDCs (Fig. 3D) . Homing capacity is important for effector functions of T cell subsets in vivo. Several studies in murine models have reported that RA induces gut-homing molecules a4b7 and CCR9 on T cells, which promote their trafficking to secondary lymphoid organs in the small intestine. To explore the effect of RAMoDCs on T cells activation, we cocultured the RA-MoDCs with naïve CD4 + T cells and determined the expression of a4b7 and CCR9 on T cells. RA-MoDCs significantly induced a4b7 and CCR9 expression on T cells (Fig. 3E) . This effect was, in fact, more prominent for CCR9 compared with a4b7 ( Fig. 3E) .
Taken together, RA-MoDCs induced CD103 expression and their capacity to synthesize RA and the gut-homing receptors a4b7 and CCR9 on T cells. However, the expression of HLA-DR and the costimulatory molecules CD83 and CD86 was suppressed.
RA-MoDCs induce IFN-g in nonpolarized conditions
through an IL-12-independent cell-cell interaction (Fig. 4A) . As expected, FOXP3 + T cells were also increased (Fig.  4A) . Surprisingly, double-positive IFN-g + FOXP3 + T cells were also significantly high in this condition (Fig. 4A) . However, RAMoDCs inhibited IL-17 + and IL-9 + T cells compared with the MoDC-primed T cells ( Fig. 4B and C) . To investigate further whether the IFN-g production from T cells is a result of soluble factors released by the DCs or cell-cell interaction, we cultured MoDCs and RA-MoDCs, along with the naïve CD4 + T cell, in a transwell assay, such that there was no cell-cell interaction between the DCs and the T cells. T-MoDCs had a significantly higher IFN-g and IL-17 initiation compared with T-RADCs (Fig. 4D) . Subsequently, we also checked the inflammatory cytokines that are known to promote Th1 differentiation. Similar to the transwell data, MoDCs had an increased IL-12 and IL-18 mRNA expression compared with RA-MoDCs (Fig. 4E) . We further checked IL-10 expression to investigate whether RA confers regulatory properties on DCs, as suggested in previous reports [27] . Surprisingly, we observed a significant reduction in IL-10 mRNA expression on RAMoDCs (Fig. 4F) . These data suggest that Th1 differentiation by RA-MoDCs is a cell-cell interaction and is independent of IL-12.
RA-MoDCs induce IFN-g in Th1, Th17, and Th9 polarizing conditions
Subsequently, we looked into the fate of lineage cytokines under their respective polarizing conditions (Th1, Th17, and Th9). RA-MoDCs and MoDCs were cocultured with naïve CD4 + T cells in the presence of specific cytokine cocktails, as mentioned in Materials and Methods. RA, known to exhibit anti-inflammatory property, surprisingly induced IFN-g + T cells in the presence of RA-MoDCs under the Th1 condition (Fig. 5A) . On the other hand, FOXP3 + T cells, which are known to be induced in the presence of RA, were significantly inhibited in the presence of RA-MoDCs compared with MoDCs (Fig. 5A) . Likewise, in the Th17 condition, IL-17 + T cells were increased in the presence of RA-MoDCs (Fig. 5B) . Notably, again, IFN-g + T cells, along with FOXP3 + T cells, were also induced in the presence of RAMoDCs compared with MoDCs ( Fig. 5B and C) . However, FOXP3 + IFN-g + double-positive T cells, in a Th17 condition, were also increased but did not attain statistical significance (P = 0.07; Fig. 5C ).
As RA-MoDCs showed a contrasting result on Th1 and Th17 cells, we were intrigued to see its effect on Th9 cells. RA-MoDCs and MoDCs were cocultured with naïve CD4 + T cells with a Th9 skewing condition. Unlike IL-17 + T cells, IL-9 + T cells were inhibited in the presence of RA-MoDCs (Fig. 6A) . It is well known that IL-4 inhibits FOXP3, so as expected, FOXP3 + T cells were also inhibited in the presence of RA-MoDCs under a Th9 polarizing condition (Fig. 6A) . Strikingly, IFN-g + T cells were significantly induced in the presence of RA-MoDCs compared with MoDCs (Fig. 6B) . These results suggest that given the inflammatory conditions, RA-MoDC-derived RA induces IFN-g + T cells, which may contribute in severe inflammation.
DISCUSSION
RA, an active metabolite of VA, possesses immune-modulating capacity and is considered to play an important role in intestinal homeostasis. IFN-g (Th1) and IL-17 (Th17) are the major cytokines that aggravate disease activity in experimental colitis and inflammatory lesions in the gut [7, 26, 28, 29] . RA, majorly secreted by the gut epithelial cells and CD103 + DCs, reduces the expression of Tbx21 [30] and RORgt [11] , both of which are indispensable for Th1 and Th17 differentiation, and promotes FOXP3 + T cells [31, 32, 33] , thereby maintaining gut tolerance and establishing its anti-inflammatory nature. However, this view has been challenged by recent studies showing a proinflammatory aspect of RA in regulating the T cell responses in the presence of inflammation. In infections and the allograft rejection model, RA has been shown to promote inflammation by inducing IFN-g and IL-17 [34, 35] . Moreover, RALDH activity, which is essential for RA metabolism, has also been found to be increased in the inflamed region of Crohn's disease patients [36] . Likewise, Wenzel et al. [37] have shown that CD103 + DCs from colitic mice induced robust Th17 differentiation ex vivo. Because of the scarce human data on the proinflammatory role of RA, we cultured naïve CD4 + T cells in the presence of RA (100 nM), activated by anti-CD3 and anti-CD28 under Th1 and Th17 polarizing conditions. RA inhibited IFN-g + and IL-17 + CD4 + T cells and promoted FOXP3 + T cells, indicating its capability to promote its tolerogenic property even in the presence of polarizing conditions. IL-9, first characterized as a Th2 cytokine, was later identified to be produced by a new T cell subset, Th9. IL-9 has been shown to alter the intestinal barrier integrity and exaggerate the disease activity in the T cell transfer model of chronic colitis, highlighting its pathogenic role in disease progression [38] [39] [40] . However, no study has evaluated the role of RA on Th9 cell differentiation. In our study, RA inhibited IL-9 + T cells, while promoting FOXP3 + T cells. This indicated the anti-inflammatory role of RA in inhibiting Th1, Th17, and Th9 cells, all of which are essential in augmenting the inflammation. During inflammatory conditions, antigenic peptides are presented by the DCs to the T cells in the mesenteric lymph nodes, which further leads to their differentiation depending on the cytokine milieu. Therefore, we did a DC-T cell coculture assay to mimic the exact condition where RA regulates intestinal DCs and T cells to modulate mucosal immune responses. It is well documented that RA induces CD103 + DCs, which further modulates the T cell responses to promote a tolerogenic environment in the gut. Therefore, to generate CD103 + DCs, we isolated CD14 + monocytes from blood and generated MoDCs in the presence of GM-CSF and IL-4. We cultured these MoDCs in the presence of 100 nM RA, as used in the naïve CD4 + T cell experiment, but failed to generate CD103 + DC (Supplemental Fig. 1B) . Interestingly, RA levels are known to be relatively much higher in the intestine compared with other parts of the body and may affect the differentiation of various Th cell types (Th1, Th17, and Th9), directly or by priming the DCs, depending on the inflammatory conditions. Similar experiments have been performed using 1 mM RA to condition the human DCs to generate RA-MoDCs [41] . When we optimized the concentration of RA to prime DCs, we could attain the same effect at a lower dose (500 nM) and were successful in generating CD103 + RAMoDCs.
Bakdash et al. [41] have shown that RA plays a central role in generation of gut tropic a4b7 + and CCR9 + T effector cells. Likewise, we have shown that the generated RA-MoDCs resemble IL-12-independent IFN-g [42] . Furthermore, there are reports where RA acts through cell-cell interaction (costimulatory pathways) to modulate IFN-g production [43, 44] . Chau et al. [45] have reported that coculturing RA-DCs with NK cells resulted in an increased, IL-12-independent IFN-g secretion. These studies indicate that the IFN-g production in coculture experiments depended on cell-cell interaction (DC-T cell) and is not mediated by the soluble factors, such as IL-12 or IL-18. Most of the acute inflammation turns chronic as a result of the constant migration of the leukocytes. Vedolizumab is an a4b7 mAb, which has shown potential promise in the treatment of IBD [46] . Likewise, studies have shown that CCR9 blockade ameliorates the inflammation [47] . Furthermore, a4b7 is widely expressed on T and B cells, whereas CCR9 has been reported to be present on Th1 effector cells. Papadakis et al. [48] have reported that CCR9 + T cells are higher in peripheral blood of active Crohn's disease patients, whose CCR9 + T cells have been found to secrete IFN-g preferentially [49] . In our study, in the presence of RAMoDCs, we attained a drastic increase in CCR9 expression on T cells, which were also observed to have increased IFN-g production, irrespective of the polarizing conditions. In other words, CCR9 mediates the homing of IFN-g + CD4 + T cells to the intestine. This shows the inflammatory nature of these DCs induced by RA in the presence of inflammation (LPS induction). Table 1 summarizes the effect of RA on CD4 + T cells in the DC:T cell coculture assay.
For the first time, we have reported that RA inhibits Th9 differentiation. Interestingly, IFN-g induction was also significantly induced on RA-MoDC-primed T cells. In line with our findings, Murugaiyan et al. [50] have shown previously that in the EAE model, IFN-g inhibits IL-9 production through the induction of IL-27 by DCs. Therefore, it is possible that either the increased levels of IFN-g during coculture of RA-MoDCs on T cells could indirectly lower the IL-9 production, or RA may directly inhibit the IL-9 production. This aspect warrants further investigation. In summary, we report a proinflammatory role of RA during inflammation in vitro, which is contrary to its established position as being anti-inflammatory. It is also possible that RA may exert a dual role, depending on tissue type, pathologic condition, and its concentration. Furthermore, RA antagonizes Th9 cell differentiation in vitro. Our work suggests that VA has the potential to modulate Th1/Th17/Th9 balance, depending on the gut microenvironment. This Th subtype-specific regulation of VA may represent the mechanism to check the simultaneous 
activation of two arms of the T cell effector response and could be especially important in pathologic situations where Th1 and Th17 polarization is a predominant inflammation-related feature.
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